HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'HanAll Biopharma Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the HanAll Biopharma Co., Ltd.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by HanAll Biopharma Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of HanAll Biopharma Co., Ltd.
- The report provides overview of HanAll Biopharma Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses HanAll Biopharma Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features HanAll Biopharma Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate HanAll Biopharma Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for HanAll Biopharma Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HanAll Biopharma Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
HanAll Biopharma Co., Ltd. Snapshot 6
HanAll Biopharma Co., Ltd. Overview 6
Key Information 6
Key Facts 6
HanAll Biopharma Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
HanAll Biopharma Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
HanAll Biopharma Co., Ltd. - Pipeline Products Glance 13
HanAll Biopharma Co., Ltd. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
HanAll Biopharma Co., Ltd. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
HanAll Biopharma Co., Ltd. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
HanAll Biopharma Co., Ltd. - Drug Profiles 18
(atorvastatin calcium + losartan potassium) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
(amlodipine besylate + candesartan cilexetil) 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
(chlorthalidone + telmisartan) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
cobamamide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HL-143 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(candesartan cilexetil + metformin hydrochloride) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HL-036 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
somatropin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HL-156FIB 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HL-161 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
HL-176 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
HL-178 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HL-271 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HanAll Biopharma Co., Ltd. - Pipeline Analysis 32
HanAll Biopharma Co., Ltd. - Pipeline Products by Target 32
HanAll Biopharma Co., Ltd. - Pipeline Products by Route of Administration 34
HanAll Biopharma Co., Ltd. - Pipeline Products by Molecule Type 35
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action 36
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates 38
HanAll Biopharma Co., Ltd. - Dormant Projects 40
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
HL-015 43
HL-016 43
Loratadine ODT 43
HanAll Biopharma Co., Ltd. - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

HanAll Biopharma Co., Ltd., Key Information 6
HanAll Biopharma Co., Ltd., Key Facts 6
HanAll Biopharma Co., Ltd. - Pipeline by Indication, 2016 8
HanAll Biopharma Co., Ltd. - Pipeline by Stage of Development, 2016 10
HanAll Biopharma Co., Ltd. - Monotherapy Products in Pipeline, 2016 11
HanAll Biopharma Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 12
HanAll Biopharma Co., Ltd. - Pre-Registration, 2016 13
HanAll Biopharma Co., Ltd. - Phase III, 2016 14
HanAll Biopharma Co., Ltd. - Phase II, 2016 15
HanAll Biopharma Co., Ltd. - Phase I, 2016 16
HanAll Biopharma Co., Ltd. - Preclinical, 2016 17
HanAll Biopharma Co., Ltd. - Pipeline by Target, 2016 32
HanAll Biopharma Co., Ltd. - Pipeline by Route of Administration, 2016 34
HanAll Biopharma Co., Ltd. - Pipeline by Molecule Type, 2016 35
HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 36
HanAll Biopharma Co., Ltd. - Recent Pipeline Updates, 2016 38
HanAll Biopharma Co., Ltd. - Dormant Developmental Projects,2016 40
HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products, 2016 43
HanAll Biopharma Co., Ltd., Other Locations 44